Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2006

View Archived Issues

Q2 review at Schering-Plough

Phase III study of MyVax in follicular NHL recommended to continue

Exclusivity period expires for business combination of BCY LifeSciences with Pipex

NicAlert to be used in new smoking cessation study

NAP treatment beneficial in model of neonatal encephalopathy

Caspase inhibition with z-VAD-FMK attenuates immediate islet mass loss in transplanted mice

Annamycin and WP-744 selectively induce apoptosis of donor T cells allowing transplant tolerance

Cardioprotective effects of a new amphiphilic spin-trap derived from PBN

Protectan CBLB-502 demonstrates effectiveness in ARS in primates

Phyton Biotech to develop Iplex manufacturing process

New Novavax vaccine to protect against H5N1 clade 2 influenza virus

AMDL compiles FDA requested data for DR-70 cancer test

sBLA filed for CAIV-T in young children

Receptor BioLogix acquires cancer vaccine Insegia

Phase III PolyHeme study completes enrollment

European orphan drug status recommended for BiovaxID in follicular lymphoma

Pozen to submit full response to Trexima approvable letter in Q4

Phase I study findings for IV DNA + protein vaccine DP6-001

Tavocept fails to meet endpoints in phase III neuropathy trials

Schering hit by insufficient results for sargramostim and Ultravist recall

Temodal approved in Japan for malignant glioma

Remicade approved in Europe as monotherapy for psoriatic arthritis

Chantix now available in U.S.

Novel therapeutic agents for HIV infection reported by Tibotec, Pfizer

Novel agents for HCV and gastric emptying cited in recent patents

European approval for NovoRapid in pregnant women with diabetes

Bristol-Myers Squibb patents novel coagulation Factor VIIa inhibitors

Vernalis reports on novel PDEIII/IV inhibitors with bronchodilator and antiinflammatory activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...